Amphastar Pharmaceuticals, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Amphastar Pharmaceuticals, Inc. (AMPH) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$15.66 million for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-08-09
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$9.56M.
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$6.09M.
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was -$7.11M.
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was -$14.96M.
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$39.50M.
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$16.93M.
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$39.77M.
- Amphastar Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$18.30M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-06-30 | -$9.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$15.66M 10-Q · filed 2017-08-09 | -$22.77M derived: sum of 3 quarters · filed 2017-08-09 | -$37.73M derived: sum of 4 quarters · filed 2017-08-09 |
| 2017-03-31 | -$6.09M 10-Q · filed 2017-05-10 | -$13.21M derived: sum of 2 quarters · filed 2017-05-10 | -$28.17M derived: sum of 3 quarters · filed 2017-05-10 | -$36.17M derived: sum of 4 quarters · filed 2017-08-09 |
| 2016-12-31 | -$7.11M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$22.07M derived: sum of 2 quarters · filed 2017-03-15 | -$30.08M derived: sum of 3 quarters · filed 2017-08-09 | -$39.50M 10-K · filed 2017-03-15 |
| 2016-09-30 | -$14.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$22.97M derived: sum of 2 quarters · filed 2017-08-09 | -$32.39M 10-Q · filed 2016-11-09 | -$36.85M derived: sum of 4 quarters · filed 2017-08-09 |
| 2016-06-30 | -$8.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$17.43M 10-Q · filed 2017-08-09 | -$21.89M derived: sum of 3 quarters · filed 2017-08-09 | -$25.59M derived: sum of 4 quarters · filed 2017-08-09 |
| 2016-03-31 | -$9.42M 10-Q · filed 2017-05-10 | -$13.88M derived: sum of 2 quarters · filed 2017-05-10 | -$17.58M derived: sum of 3 quarters · filed 2017-05-10 | -$21.30M derived: sum of 4 quarters · filed 2017-05-10 |
| 2015-12-31 | -$4.46M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$8.16M derived: sum of 2 quarters · filed 2017-03-15 | -$11.88M derived: sum of 3 quarters · filed 2017-03-15 | -$16.93M 10-K · filed 2017-03-15 |
| 2015-09-30 | -$3.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$7.42M derived: sum of 2 quarters · filed 2016-11-09 | -$12.47M 10-Q · filed 2016-11-09 | -$22.39M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | -$3.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$8.76M 10-Q · filed 2016-08-09 | -$18.69M derived: sum of 3 quarters · filed 2017-03-15 | -$21.82M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-03-31 | -$5.04M 10-Q · filed 2016-05-10 | -$14.97M derived: sum of 2 quarters · filed 2017-03-15 | -$18.10M derived: sum of 3 quarters · filed 2017-03-15 | -$40.02M derived: sum of 4 quarters · filed 2017-03-15 |
| 2014-12-31 | -$9.93M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$13.06M derived: sum of 2 quarters · filed 2017-03-15 | -$34.98M derived: sum of 3 quarters · filed 2017-03-15 | -$39.77M 10-K · filed 2017-03-15 |
| 2014-09-30 | -$3.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | -$25.05M derived: sum of 2 quarters · filed 2015-11-13 | -$29.84M 10-Q · filed 2015-11-13 | -$33.01M derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-06-30 | -$21.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | -$26.71M 10-Q · filed 2015-08-13 | -$29.88M derived: sum of 3 quarters · filed 2016-03-15 | -$34.96M derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-03-31 | -$4.80M 10-Q · filed 2015-05-14 | -$7.97M derived: sum of 2 quarters · filed 2016-03-15 | -$13.04M derived: sum of 3 quarters · filed 2016-03-15 | |
| 2013-12-31 | -$3.17M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$8.25M derived: sum of 2 quarters · filed 2016-03-15 | -$18.30M 10-K · filed 2016-03-15 | |
| 2013-09-30 | -$5.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | -$15.13M 10-Q · filed 2014-11-13 | ||
| 2013-06-30 | -$10.05M 10-Q · filed 2014-08-13 | |||
| 2012-12-31 | -$25.11M 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |